119 related articles for article (PubMed ID: 24602567)
1. The use of lipid-coated nanodiamond to improve bioavailability and efficacy of sorafenib in resisting metastasis of gastric cancer.
Zhang Z; Niu B; Chen J; He X; Bao X; Zhu J; Yu H; Li Y
Biomaterials; 2014 May; 35(15):4565-72. PubMed ID: 24602567
[TBL] [Abstract][Full Text] [Related]
2. Improving Oral Bioavailability of Sorafenib by Optimizing the "Spring" and "Parachute" Based on Molecular Interaction Mechanisms.
Liu C; Chen Z; Chen Y; Lu J; Li Y; Wang S; Wu G; Qian F
Mol Pharm; 2016 Feb; 13(2):599-608. PubMed ID: 26709621
[TBL] [Abstract][Full Text] [Related]
3. Heparin-functionalized Pluronic nanoparticles to enhance the antitumor efficacy of sorafenib in gastric cancers.
Yang YC; Cai J; Yin J; Zhang J; Wang KL; Zhang ZT
Carbohydr Polym; 2016 Jan; 136():782-90. PubMed ID: 26572413
[TBL] [Abstract][Full Text] [Related]
4. Sorafenib inhibits 5-fluorouracil-resistant gastric cancer cell growth.
Kim HM; Kim SA; Park SB; Cho JH; Song SY
Scand J Gastroenterol; 2017 May; 52(5):577-584. PubMed ID: 28110575
[TBL] [Abstract][Full Text] [Related]
5. Fabrication of poly (butadiene-block-ethylene oxide) based amphiphilic polymersomes: An approach for improved oral pharmacokinetics of Sorafenib.
Khan MA; Ali S; Venkatraman SS; Sohail MF; Ovais M; Raza A
Int J Pharm; 2018 May; 542(1-2):196-204. PubMed ID: 29551745
[TBL] [Abstract][Full Text] [Related]
6. Improved Oral Bioavailability and Liver Targeting of Sorafenib Solid Lipid Nanoparticles in Rats.
Wang H; Wang H; Yang W; Yu M; Sun S; Xie B
AAPS PharmSciTech; 2018 Feb; 19(2):761-768. PubMed ID: 28983849
[TBL] [Abstract][Full Text] [Related]
7. Codelivery of sorafenib and curcumin by directed self-assembled nanoparticles enhances therapeutic effect on hepatocellular carcinoma.
Cao H; Wang Y; He X; Zhang Z; Yin Q; Chen Y; Yu H; Huang Y; Chen L; Xu M; Gu W; Li Y
Mol Pharm; 2015 Mar; 12(3):922-31. PubMed ID: 25622075
[TBL] [Abstract][Full Text] [Related]
8. Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients.
Huillard O; Boissier E; Blanchet B; Thomas-Schoemann A; Cessot A; Boudou-Rouquette P; Durand JP; Coriat R; Giroux J; Alexandre J; Vidal M; Goldwasser F
Expert Opin Drug Saf; 2014 May; 13(5):663-73. PubMed ID: 24693873
[TBL] [Abstract][Full Text] [Related]
9. Improving anti-tumor activity of sorafenib tosylate by lipid- and polymer-coated nanomatrix.
Guo Y; Zhong T; Duan XC; Zhang S; Yao X; Yin YF; Huang D; Ren W; Zhang Q; Zhang X
Drug Deliv; 2017 Nov; 24(1):270-277. PubMed ID: 28165798
[TBL] [Abstract][Full Text] [Related]
10. Galactosylated polymeric carriers for liver targeting of sorafenib.
Craparo EF; Sardo C; Serio R; Zizzo MG; Bondì ML; Giammona G; Cavallaro G
Int J Pharm; 2014 May; 466(1-2):172-80. PubMed ID: 24607205
[TBL] [Abstract][Full Text] [Related]
11. Lipid nanocarriers containing sorafenib inhibit colonies formation in human hepatocarcinoma cells.
Bondì ML; Botto C; Amore E; Emma MR; Augello G; Craparo EF; Cervello M
Int J Pharm; 2015 Sep; 493(1-2):75-85. PubMed ID: 26211902
[TBL] [Abstract][Full Text] [Related]
12. miR-542-3p Appended Sorafenib/All-trans Retinoic Acid (ATRA)-Loaded Lipid Nanoparticles to Enhance the Anticancer Efficacy in Gastric Cancers.
Li T; Zhang Y; Meng YP; Bo LS; Ke WB
Pharm Res; 2017 Dec; 34(12):2710-2719. PubMed ID: 29181687
[TBL] [Abstract][Full Text] [Related]
13. An investigation of the effect of sorafenib on tumour growth and recurrence after liver cancer resection in nude mice independent of phosphorylated extracellular signal-regulated kinase levels.
Wang Z; Hu J; Qiu SJ; Huang XW; Dai Z; Tan CJ; Zhou J; Fan J
Expert Opin Investig Drugs; 2011 Aug; 20(8):1039-45. PubMed ID: 21671804
[TBL] [Abstract][Full Text] [Related]
14. Polymeric micelles incorporating (1,2-diaminocyclohexane)platinum (II) suppress the growth of orthotopic scirrhous gastric tumors and their lymph node metastasis.
Rafi M; Cabral H; Kano MR; Mi P; Iwata C; Yashiro M; Hirakawa K; Miyazono K; Nishiyama N; Kataoka K
J Control Release; 2012 Apr; 159(2):189-96. PubMed ID: 22326402
[TBL] [Abstract][Full Text] [Related]
15. Physiologically based pharmacokinetic models for everolimus and sorafenib in mice.
Pawaskar DK; Straubinger RM; Fetterly GJ; Hylander BH; Repasky EA; Ma WW; Jusko WJ
Cancer Chemother Pharmacol; 2013 May; 71(5):1219-29. PubMed ID: 23455451
[TBL] [Abstract][Full Text] [Related]
16. Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression.
Cao H; Zhang Z; Zhao S; He X; Yu H; Yin Q; Zhang Z; Gu W; Chen L; Li Y
J Control Release; 2015 May; 205():162-71. PubMed ID: 25598420
[TBL] [Abstract][Full Text] [Related]
17. Nanodiamonds-mediated doxorubicin nuclear delivery to inhibit lung metastasis of breast cancer.
Xiao J; Duan X; Yin Q; Zhang Z; Yu H; Li Y
Biomaterials; 2013 Dec; 34(37):9648-56. PubMed ID: 24016858
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib suppresses the rapid progress of hepatocellular carcinoma after insufficient radiofrequency ablation therapy: an experiment in vivo.
Xu M; Xie XH; Xie XY; Xu ZF; Liu GJ; Zheng YL; Huang GL; Wang W; Zheng SG; Lü MD
Acta Radiol; 2013 Mar; 54(2):199-204. PubMed ID: 23171528
[TBL] [Abstract][Full Text] [Related]
19. Adaptive immune cells are necessary for the enhanced therapeutic effect of sorafenib-loaded nanoparticles.
Zhao ZB; Long J; Zhao YY; Yang JB; Jiang W; Liu QZ; Yan K; Li L; Wang YC; Lian ZX
Biomater Sci; 2018 Mar; 6(4):893-900. PubMed ID: 29512660
[TBL] [Abstract][Full Text] [Related]
20. Spontaneous regression of metastatic papillary renal cell cancer after cessation of treatment with sorafenib.
Grenader T; Rosenbaum E; Zilber S; Bogot N; Shavit L
Clin Genitourin Cancer; 2013 Jun; 11(2):201-3. PubMed ID: 23266054
[No Abstract] [Full Text] [Related]
[Next] [New Search]
